FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387518433> ?p ?o ?g. }

• W4387518433 abstract "Abstract Background The opening of pannexin1 channels is considered as a key event in inflammation. Pannexin1 channel-mediated release of adenosine triphosphate triggers inflammasome signaling and activation of immune cells. By doing so, pannexin1 channels play an important role in several inflammatory diseases. Although pannexin1 channel inhibition could represent a novel clinical strategy for treatment of inflammatory disorders, therapeutic pannexin1 channel targeting is impeded by the lack of specific, potent and/or in vivo-applicable inhibitors. The goal of this study is to generate nanobody-based inhibitors of pannexin1 channels. Results Pannexin1-targeting nanobodies were developed as potential new pannexin1 channel inhibitors. We identified 3 cross-reactive nanobodies that showed affinity for both murine and human pannexin1 proteins. Flow cytometry experiments revealed binding capacities in the nanomolar range. Moreover, the pannexin1-targeting nanobodies were found to block pannexin1 channel-mediated release of adenosine triphosphate. The pannexin1-targeting nanobodies were also demonstrated to display anti-inflammatory effects in vitro through reduction of interleukin 1 beta amounts. This anti-inflammatory outcome was reproduced in vivo using a human-relevant mouse model of acute liver disease relying on acetaminophen overdosing. More specifically, the pannexin1-targeting nanobodies lowered serum levels of inflammatory cytokines and diminished liver damage. These effects were linked with alteration of the expression of several NLRP3 inflammasome components. Conclusions This study introduced for the first time specific, potent and in vivo-applicable nanobody-based inhibitors of pannexin1 channels. As demonstrated for the case of liver disease, the pannexin1-targeting nanobodies hold great promise as anti-inflammatory agents, yet this should be further tested for extrahepatic inflammatory disorders. Moreover, the pannexin1-targeting nanobodies represent novel tools for fundamental research regarding the role of pannexin1 channels in pathological and physiological processes. Graphical Abstract" @default.
• W4387518433 created "2023-10-12" @default.
• W4387518433 creator A5023971009 @default.
• W4387518433 creator A5041691799 @default.
• W4387518433 creator A5045862213 @default.
• W4387518433 creator A5056011321 @default.
• W4387518433 creator A5059511936 @default.
• W4387518433 creator A5067597833 @default.
• W4387518433 creator A5086007558 @default.
• W4387518433 date "2023-10-11" @default.
• W4387518433 modified "2023-10-13" @default.
• W4387518433 title "Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury" @default.
• W4387518433 cites W1758955113 @default.
• W4387518433 cites W1969353708 @default.
• W4387518433 cites W1973702904 @default.
• W4387518433 cites W1987581929 @default.
• W4387518433 cites W2017612052 @default.
• W4387518433 cites W2021032684 @default.
• W4387518433 cites W2030872418 @default.
• W4387518433 cites W2042259903 @default.
• W4387518433 cites W2053319140 @default.
• W4387518433 cites W2061455807 @default.
• W4387518433 cites W2062961514 @default.
• W4387518433 cites W2076907204 @default.
• W4387518433 cites W2079350327 @default.
• W4387518433 cites W2083119828 @default.
• W4387518433 cites W2086204051 @default.
• W4387518433 cites W2088080828 @default.
• W4387518433 cites W2102694854 @default.
• W4387518433 cites W2171720135 @default.
• W4387518433 cites W2338188328 @default.
• W4387518433 cites W2510233222 @default.
• W4387518433 cites W2531441777 @default.
• W4387518433 cites W2555250785 @default.
• W4387518433 cites W2558163233 @default.
• W4387518433 cites W2594371417 @default.
• W4387518433 cites W2727006191 @default.
• W4387518433 cites W2736010006 @default.
• W4387518433 cites W2742103419 @default.
• W4387518433 cites W2742777852 @default.
• W4387518433 cites W2750288137 @default.
• W4387518433 cites W2754901959 @default.
• W4387518433 cites W2769445535 @default.
• W4387518433 cites W2772827896 @default.
• W4387518433 cites W2786064874 @default.
• W4387518433 cites W2886940549 @default.
• W4387518433 cites W2896640337 @default.
• W4387518433 cites W2896698487 @default.
• W4387518433 cites W2901976301 @default.
• W4387518433 cites W2909106560 @default.
• W4387518433 cites W2947219032 @default.
• W4387518433 cites W2957275599 @default.
• W4387518433 cites W2972031537 @default.
• W4387518433 cites W2974579689 @default.
• W4387518433 cites W2980582743 @default.
• W4387518433 cites W2981914489 @default.
• W4387518433 cites W2983988502 @default.
• W4387518433 cites W2999714365 @default.
• W4387518433 cites W3027562820 @default.
• W4387518433 cites W3090132117 @default.
• W4387518433 cites W3121110678 @default.
• W4387518433 cites W3125964370 @default.
• W4387518433 cites W3163234606 @default.
• W4387518433 cites W3185098071 @default.
• W4387518433 cites W3186904131 @default.
• W4387518433 cites W3187782388 @default.
• W4387518433 cites W4210642052 @default.
• W4387518433 cites W4211175126 @default.
• W4387518433 cites W4214841746 @default.
• W4387518433 cites W4226187119 @default.
• W4387518433 cites W4283172499 @default.
• W4387518433 cites W4288045797 @default.
• W4387518433 cites W4292695883 @default.
• W4387518433 cites W4293484054 @default.
• W4387518433 cites W4376602555 @default.
• W4387518433 doi "https://doi.org/10.1186/s12951-023-02137-1" @default.
• W4387518433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37821897" @default.
• W4387518433 hasPublicationYear "2023" @default.
• W4387518433 type Work @default.
• W4387518433 citedByCount "0" @default.
• W4387518433 crossrefType "journal-article" @default.
• W4387518433 hasAuthorship W4387518433A5023971009 @default.
• W4387518433 hasAuthorship W4387518433A5041691799 @default.
• W4387518433 hasAuthorship W4387518433A5045862213 @default.
• W4387518433 hasAuthorship W4387518433A5056011321 @default.
• W4387518433 hasAuthorship W4387518433A5059511936 @default.
• W4387518433 hasAuthorship W4387518433A5067597833 @default.
• W4387518433 hasAuthorship W4387518433A5086007558 @default.
• W4387518433 hasBestOaLocation W43875184331 @default.
• W4387518433 hasConcept C150903083 @default.
• W4387518433 hasConcept C185592680 @default.
• W4387518433 hasConcept C203014093 @default.
• W4387518433 hasConcept C207001950 @default.
• W4387518433 hasConcept C2776914184 @default.
• W4387518433 hasConcept C2777209026 @default.
• W4387518433 hasConcept C502942594 @default.
• W4387518433 hasConcept C71924100 @default.
• W4387518433 hasConcept C86803240 @default.
• W4387518433 hasConcept C95444343 @default.
• W4387518433 hasConcept C98274493 @default.

• next